Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39 GBX | -.--% |
|
-1.27% | -6.02% |
Sales 2024 * | 44.51B 379M 29.95B | Sales 2025 * | 50.42B 429M 33.93B | Capitalization | 52.69B 448M 35.46B |
---|---|---|---|---|---|
Net income 2024 * | 5.25B 44.7M 3.53B | Net income 2025 * | 6.24B 53.15M 4.2B | EV / Sales 2024 * | 1.32 x |
Net Debt 2024 * | 5.96B 50.7M 4.01B | Net Debt 2025 * | 878M 7.48M 591M | EV / Sales 2025 * | 1.06 x |
P/E ratio 2024 * |
9.6
x | P/E ratio 2025 * |
7.82
x | Employees | 5,700 |
Yield 2024 * |
3.52% | Yield 2025 * |
4.45% | Free-Float | 76.68% |
1 week | -1.27% | ||
1 month | +1.30% | ||
6 months | -6.02% | ||
Current year | -6.02% |
![Extreme 38.2](/images/extremecours_fleche.png)
![Extreme 37.15](/images/extremecours_fleche.png)
![Extreme 33.555](/images/extremecours_fleche.png)
![Extreme 33.555](/images/extremecours_fleche.png)
![Extreme 33.3](/images/extremecours_fleche.png)
![Extreme 28.0695](/images/extremecours_fleche.png)
![Extreme 10.1009](/images/extremecours_fleche.png)
Managers | Title | Age | Since |
---|---|---|---|
Director of Finance/CFO | 61 | 31/12/89 | |
Chief Tech/Sci/R&D Officer | - | - | |
Selina Akter
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | - | 31/12/75 | |
Founder | - | 31/12/75 | |
Iqbal Ahmed
CEO | Chief Executive Officer | - | 31/12/84 |
Date | Price | Change | Volume |
---|---|---|---|
28/06/24 | 39 | -.--% | 10,000 |
27/06/24 | 39 | -.--% | 5,662 |
26/06/24 | 39 | -1.27% | 60,046 |
25/06/24 | 39.5 | -.--% | 48,800 |
24/06/24 | 39.5 | -.--% | 92,167 |
Delayed Quote London S.E., June 28, 2024 at 04:35 pm
More quotes![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+55.32% | 815B | |
+44.05% | 641B | |
-6.75% | 352B | |
+13.56% | 314B | |
+10.68% | 303B | |
+16.57% | 242B | |
+2.04% | 224B | |
+13.31% | 218B | |
+8.48% | 168B |
- Stock Market
- Equities
- BXPHARMA Stock
- BXP Stock